Istradefylline effect on Parkinson’s Disease Tremor, Motor symptoms and non-Motor symptoms.
Objective: Istradefylline is FDA approved for use in patients with PD treated with carbidopa-levodopa to reduce off time. GUH Movement Disorder Group has observed that…Progression of the Clinical Features of Progressive Supranuclear Palsy-Richardson Syndrome in Early and Advanced Stages
Objective: We sought to evaluate PSP-Richardson syndrome (PSP-RS) for uniformity of progression over nearly the entire disease course. Rather than comparing scores to the simple…Honey prevented MPTP-induced oxidative stress, neuroinflammation and gliosis in adult male Swiss mice.
Objective: To investigate the neuroprotective role of honey against oxidative stress and neuroinflammation induced by MPTP in adult male Swiss mice. Background: Oxidative stress and…Validation of the Patient Reported Outcomes in Parkinson’s Disease scale in outpatients
Objective: To validate PRO-PD in a random sample of outpatients with PD. Background: Successful treatment of Parkinson's disease (PD) requires symptom monitoring. Patient-Reported Outcomes in…MDS-UPDRS Part 3 cannot be summed with other parts of the MDS-UPDRS: a clinimetric evaluation
Objective: To establish whether summing scores of Movement Disorder Society– sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part 3 (Motor Examination) with…An IMU- based Objective Quantification Method for Bradykinesia Evaluation in Parkinson’s disease
Objective: Proposing an inertial measurement unit (IMU)-based objective quantification method for bradykinesia evaluation in Parkinson’s disease (PD) using MDS UPDRS III. Background: MDS-UPDRS III rating…Comparative whole transcriptome analysis of human and mice models of Parkinson’s disease bearing defective glucocerebrosidase activity revealed alteration of expression profile of genes involved in the autophagy
Objective: To identify potential biomarkers of Parkinson's disease (PD) associated with dysfunction of enzyme glucocerebrosidase (GCase) by a comparative whole transcriptome analysis of animal models…Self-report vs. informant-report of problematic behaviors using the Huntington’s Disease-Behavioral Questionnaire
Objective: To examine the utility of a new behavioral measure, the Huntington’s Disease–Behavioral Questionnaire (HD-BQ) (Hughes et al, 2023), in individuals with Huntington’s disease (HD).…Functional brain network alterations in the prodromal phase of X-linked dystonia-parkinsonism
Objective: To determine whether functional connectivity changes are already present in non-manifesting carriers (NMCs) of the TAF1 gene mutation causing X-linked dystonia-parkinsonism (XDP). Background: XDP…Subjective assessment of parkinson’s disease in relation to changes in brain microstructure
Objective: To elucidate the relationship between these subjective and objective ratings of PDQ-39 and the changes in brain microstructure. Background: PDQ-39 has been used to…
- « Previous Page
- 1
- …
- 136
- 137
- 138
- 139
- 140
- …
- 186
- Next Page »